We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
PAO Group Inc (PK) | USOTC:PAOG | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0003 | 0.0003 | 0.0004 | 0.0004 | 0.0003 | 0.0004 | 329,691 | 14:31:00 |
December 1, 2021 -- InvestorsHub NewsWire -- via pennymillions --
Tissue culture itself is not new, but its new to the cannabis industry. See a recent MJBizDaily article to learn more about the future of cannabis tissue culture displacing cloning.
Pharmagreen Biotech, Inc. (PHBI) is set to catch the tissue culture wave with its own proprietary tissue culture technology now gaining more presence in the market place.
PHBI recently published news on the company’s development of tissue cultures for the cannabis market in California:
Pharmagreen Prepares for Entry Into the Multi-Billion Dollar California Cannabis Industry
Puration, Inc. (PURA) and PAO Group, Inc. (PAOG) recently expressed interest in bringing tissue culture into their own developments and specifically made mention of PHBI.
PHBI’s proprietary tissue culture has massive industry potential as regulations for legal cannabis cultivation expand and evolve requiring higher and higher standards for clean plants with consistent genetic strains, not to mention maintaining consistent competitive quality differentiation.
With less than 300 million shares in the float and less than 300 million shares issued and out, PHBI has the potential to make big moves on news.
Source - https://www.pennymillions.com/blog/the-next-big-cannabis-innovation-tissue-culture
Other stocks on the move include OWUV.
SOURCE: pennymillions
1 Year PAO (PK) Chart |
1 Month PAO (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions